Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.45 |
| ▸ | CA1 | P00915 | 5/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28371689 | 0.91 | ZDHHC7 (0.48) | CA2ZDHHC7FDPSGPR84FFAR1 | |
| SCHEMBL5167402 | 0.86 | — | — | |
| SCHEMBL1784628 | 0.82 | CA2 (0.45) | CA2CA1MAPK1ZDHHC7FDPS | |
| SCHEMBL26940441 | 0.82 | CA2 (0.50) | CA2CA1MAPK1ZDHHC7TDP1 | |
| SCHEMBL192696 | 0.82 | CA2 (0.50) | CA2CA1MAPK1ZDHHC7TDP1 | |
| SCHEMBL25582929 | 0.80 | CA2 (0.52) | CA2CA1MAPK1ZDHHC7FDPS | |
| SCHEMBL16908584 | 0.80 | CA2 (0.52) | CA2CA1MAPK1ZDHHC7FDPS | |
| SCHEMBL6695690 | 0.80 | CA2 (0.44) | CA2CA1MAPK1ZDHHC7FDPS | |
| SCHEMBL5200841 | 0.80 | CA2 (0.59) | CA2CA1MAPK1ZDHHC7CYP3A4 | |
| SCHEMBL5163491 | 0.80 | CA2 (0.39) | CA2CA1MAPK1ZDHHC7FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1772150-A1 | Benzothiophene formulations of a specific dosage | Eli Lilly & Company (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060106010-A1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
| US-RE39049-E1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| US-RE38968-E1 | Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride | ELI LILLY AND COMPANY (US) | 2006-02-07 | — | — | US | disclosed |
| EP-1438957-A1 | Benzothiophene formulations of a specific dosage | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030212058-A1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY | 2003-11-13 | — | — | US | disclosed |
| EP-1238667-A2 | Use of benzothiophenes for treatment of hypercholesterolaemia | ELI LILLY AND COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-0693285-B1 | Pharmaceutical compositions containing a bisphosphonate and an anti-resorptive agent for inhibiting bone loss | LILLY CO ELI (US) | 2002-02-06 | — | — | EP | disclosed |
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | BLACK LARRY J (US) | 2001-12-13 | — | — | US | disclosed |
| EP-0635264-B1 | Antiestrogenic 2-phenyl-3-aroylbenzothiophenes as hypoglycemic agents | LILLY CO ELI (US) | 1997-09-10 | — | — | EP | disclosed |
| US-5457117-A | Method for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[B][2-(piperidin-1-yl)ethoxyphenylimethanone hydrochloride | ELI LILLY AND COMPANY (US) | 1995-10-10 | — | — | US | disclosed |
| US-5441964-A | Especially post-memopausal women | ELI LILLY AND COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| EP-0665015-A2 | Combination treatment for osteoporosis | ELI LILLY AND COMPANY (US) | 1995-08-02 | — | — | EP | disclosed |
| EP-0657162-A1 | Methods for lowering serum cholesterol | ELI LILLY AND COMPANY (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0651998-A1 | Methods for inhibiting bone loss | ELI LILLY AND COMPANY (US) | 1995-05-10 | — | — | EP | disclosed |
| EP-0650724-A1 | Methods for inhibiting uterine fibrosis | ELI LILLY AND COMPANY (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5393763-A | Administering benzothiophenes such as raloxifene hydrochloride | ELI LILLY AND COMPANY (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0635264-A2 | Antiestrogens as hypoglycemic agents | ELI LILLY AND COMPANY (US) | 1995-01-25 | — | — | EP | disclosed |
| EP-0605193-A1 | Use of benzothiophenes for treatment of hypercholesterolaemia | ELI LILLY AND COMPANY (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0584952-A1 | Improvements in or relating to benzothiophenes | ELI LILLY AND COMPANY (US) | 1994-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106010-A1 | Methods for inhibiting bone loss | SHBG, SOST, ESRRB | CA2 638/4885CA1 1849/4885MAPK1 3669/4885 |
| US-20030212058-A1 | Methods for inhibiting bone loss | SHBG, SOST, ESRRB | CA2 638/4885CA1 1849/4885MAPK1 3669/4885 |
| US-20010051636-A1 | Combination treatment for inhibiting bone loss | SOST, BMP2, PTH1R | CA2 218/4885CA1 3527/4885MAPK1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.